


THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A compound of the formula (I)



wherein:

- 5 R_2 is selected from hydrogen, hydroxyl, O-alkyl, O-alkenyl, O-benzoyl, O-dibenzoyl, O-alkanoyl, O-alkenoyl, O-aryl, O-heterocyclic, O-heteroaryl or



- 10 wherein R_5 and R_7 are independently be selected from hydrogen, alkanoyl, alkenoyl, dibenzoyl, benzoyl or benzoyl alkyl substituted alkanoyl;
 R_3 is selected from hydroxyl, O-alkanoyl, O-alkenoyl, O-benzoyl, O-dibenzoyl, O-alkyl, O-alkenyl, O-aryl, O-heterocyclic or O-heteroaryl;
 R_4 is selected from $-CH_2OH$, $COOH$, CH_2OCOCH_3 , COO alkyl, COO aryl, CH_2COO alkyl, COO -heterocyclic, COO -heteroaryl, CH_2-O aryl, CH_2O heterocyclic or CH_2O heteroaryl;
 15 R_6 is selected from hydrogen or



R_7 is selected from hydrogen or alkyl; or
 pharmaceutically acceptable salts thereof with the proviso that
 when R_2 is OH, R_3 is OH, R_4 is CH_2OH , R_6 is xylopyranosyl, R_1 cannot be
 4.

- 5 2. A compound as claimed in claim 1 wherein R_2 is hydrogen,
 benzoyl, dibenzoyl, tigloyl or



wherein R_5 and R_7 are selected from hydrogen, tigloyl, benzoyl or
 benzoyl alkyl substituted alkanoyl.

- 10 3. A compound as claimed in claim 1 wherein R_3 is selected from O-
 acetyl, O-benzoyl, O-dibenzoyl, O-isobutyryl or O-tigloyl.
4. A compound as claimed in claim 1 wherein R_4 is selected from
 CH_2OH , O-acetyl or hydroxy.
- 15 5. A compound as claimed in claim 1 wherein R_2 is arabino pyranosyl, 3-
 (3-benzoyl-2-methylbutanoyl)-4-benzoyl- α -L-arabinopyranosyl, O-benzoyl, O-
 dibenzoyl, O-tigloyl, 3,4 dibenzoyl α -L-arabinopyranosyl, 3-(3-benzoyl-2-
 methylbutyryl)-4-tigloyl- α -L-arabinopyranosyl, 3-tigloyl-4-(3-benzoyl-2-
 methylbutyryl)- α -L-arabinopyranosyl, 3-(3-benzoyl-2 methyl butanoyl)-4-
 benzoyl- α -L-arabinopyranosyl or 3-(3-benzoyl-2 methylbutyryl)-4-benzoyl- α -
 20 L-arabinopyranosyl.
6. A compound as claimed in claim 1 wherein R_6 is methyl.
7. 3-O- β -D-xylopyranosyl(1 \rightarrow 3)-[β -D-galactopyranosyl(1 \rightarrow 2)]- β -D-
 glucuronopyranosyl-21-O-[3-(3-benzoyl-2-methylbutanoyl)-4-benzoyl- α -L-
 arabinopyranosyl]-22-O-acetyl barringtonol C;
- 25 8. 3-O- β -D-xylopyranosyl(1 \rightarrow 3)-[β -D-galactopyranosyl(1 \rightarrow 2)]- β -D-

- glucuronopyranosyl-21-O-benzoyl barringtogenol C;
9. 3-O- β -D-xylopyranosyl(1 \rightarrow 3)-[β -D-galactopyranosyl(1 \rightarrow 2)]- β -D-glucuronopyranosyl-21-O-benzoyl-28-O-acetyl barringtogenol C;
10. 3-O- β -D-xylopyranosyl(1 \rightarrow 3)-[β -D-galactopyranosyl(1 \rightarrow 2)]- β -D-glucuronopyranosyl-21-O-benzoyl-22-O-isobutyryl barringtogenol C;
11. 3-O- β -D-xylopyranosyl(1 \rightarrow 3)-[β -D-galactopyranosyl(1 \rightarrow 2)]- β -D-methylglucuronopyranosyl-21,22-O-dibenzoyl barringtogenol C;
12. 3-O- β -D-xylopyranosyl(1 \rightarrow 3)-[β -D-galactopyranosyl(1 \rightarrow 2)]- β -D-glucuronopyranosyl-21, 22-O-dibenzoyl barringtogenol C;
13. 3-O- β -D-xylopyranosyl(1 \rightarrow 3)-[β -D-galactopyranosyl(1 \rightarrow 2)]- β -D-methylglucuronopyranosyl-21-O-benzoyl-22-O-tigloyl barringtogenol C;
14. 3-O- β -D-xylopyranosyl(1 \rightarrow 3)-[β -D-galactopyranosyl(1 \rightarrow 2)]- β -D-glucuronopyranosyl-21-O-benzoyl-22-O-tigloyl barringtogenol C;
15. 3-O- β -D-xylopyranosyl(1 \rightarrow 3)-[β -D-galactopyranosyl(1 \rightarrow 2)]- β -D-methylglucuronopyranosyl-21,22-O-tigloyl barringtogenol C;
16. 3-O- β -D-xylopyranosyl(1 \rightarrow 3)-[β -D-galactopyranosyl(1 \rightarrow 2)]- β -D-glucuronopyranosyl-21,22-O-tigloyl barringtogenol C;
17. 3-O- β -D-xylopyranosyl(1 \rightarrow 3)-[β -D-galactopyranosyl(1 \rightarrow 2)]- β -D-glucuronopyranosyl-22-O-benzoyl barringtogenol C;
18. 3-O- β -D-xylopyranosyl(1 \rightarrow 3)-[β -D-galactopyranosyl(1 \rightarrow 2)]- β -D-glucuronopyranosyl-21-O-[3,4-dibenzoyl- α -L-arabinopyranosyl]-22-O-acetyl barringtogenol C;
19. 3-O- β -D-xylopyranosyl(1 \rightarrow 3)-[β -D-galactopyranosyl(1 \rightarrow 2)]- β -D-glucuronopyranosyl-21-O-[3,4-dibenzoyl- α -L-arabinopyranosyl]-28-O-acetyl barringtogenol C;
20. 3-O- β -D-xylopyranosyl(1 \rightarrow 3)-[β -D-galactopyranosyl(1 \rightarrow 2)]- β -D-glucuronopyranosyl-21-O-[3-(3-benzoyl-2-methylbutyryl)-4-tigloyl- α -L-arabinopyranosyl]-22-O-acetyl barringtogenol C;
21. 3-O- β -D-xylopyranosyl(1 \rightarrow 3)-[β -D-galactopyranosyl(1 \rightarrow 2)]- β -D-glucuronopyranosyl-21-O-[3-tigloyl-4-(3-benzoyl-2-methylbutyryl)- α -L-arabinopyranosyl]-22-O-acetyl barringtogenol C;
22. 3-O- β -D-galactopyranosyl(1 \rightarrow 2)- β -D-glucuronopyranosyl-21-O-[3-(3-

benzoyl-2-methylbutyryl)-4-benzoyl- α -L-arabinopyranosyl]-22-O-acetyl
barringtonol C; or

23. 3-O- β -D-xylopyranosyl(1 \rightarrow 3)-[β -D-galactopyranosyl(1 \rightarrow 2)]- β -D-
glucuronopyranosyl-21-O-[3-(3-benzoyl-2-methylbutyryl)-4-benzoyl- α -L-
5 arabinopyranosyl]-28-O-acetyl barringtonol C.

24. A pharmaceutical composition for treatment and/or control of pain
comprising a therapeutically effective amount of a compound of any one
of claims 1 to 23 and a pharmaceutically acceptable carrier.

25. A pharmaceutical composition as claimed in claim 24 wherein the
10 carrier is a pharmaceutically acceptable excipient.

26. A method of treating and/or controlling pain which includes the step
of administering to a subject in need of such treatment at least one
compound as claimed in any one of claims 1 to 23.